Immune checkpoint alterations and their blockade in COVID-19 patients

被引：4
|
作者：
Tan, Jiaxiong [1 ]
Li, Yangqiu [2 ]
机构：
[1] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
[2] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China
来源：
BLOOD SCIENCE | 2022年 / 4卷 / 04期
关键词：
T-CELLS; PD-1; LYMPHOCYTES; SARS-COV-2; SIGNATURE;
D O I：
10.1097/BS9.0000000000000132
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Coronavirus disease 2019 (COVID-19) is a highly contagious disease that seriously affects people's lives. Immune dysfunction, which is characterized by abnormal expression of multiple immune checkpoint proteins (ICs) on immune cells, is associated with progression and poor prognosis for tumors and chronic infections. Immunotherapy targeting ICs has been well established in modulating immune function and improving clinical outcome for solid tumors and hematological malignancies. The role of ICs in different populations or COVID-19 stages and the impact of IC blockade remains unclear. In this review, we summarized current studies of alterations in ICs in COVID-19 to better understand immune changes and provide strategies for treating COVID-19 patients, particularly those with cancer.
引用
收藏
页码：192 / 198
页数：7
相关论文
共 50 条
  • [21] COVID-19 vaccines in patients with urothelial cancers receiving immune checkpoint inhibitors.
    Gilbert, Danielle
    Hu, Junxiao
    Lam, Elaine T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review
    Ruiz, Juan I.
    Lopez-Olivo, Maria A.
    Geng, Yimin
    Suarez-Almazor, Maria E.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (02) : 103 - 110
  • [23] COVID-19 VACCINATION IN PATIENTS WITH RENAL CANCER OR MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITORS
    Hwang, Joyce
    Dzimitrowicz, Hannah
    Shah, Riddhishkumar
    Ashcraft, Kathleen
    George, Daniel
    Salama, April
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A655 - A655
  • [24] COVID-19 vaccines in patients with solid tumor cancers receiving immune checkpoint inhibitors
    Gilbert, Danielle
    Hu, Junxiao
    Lam, Elaine T.
    CANCER RESEARCH, 2023, 83 (07)
  • [25] COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors
    Mengni Guo
    Jieying Liu
    Shuntai Zhou
    James Yu
    Zohaib Ahmed
    Sarfraz Ahmad
    Manoucher Manoucheri
    Mark A. Socinski
    Tarek Mekhail
    Vincent Hsu
    SN Comprehensive Clinical Medicine, 4 (1)
  • [26] Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
    Maio, Michele
    Hamid, Omid
    Larkin, James
    Covre, Alessia
    Altomonte, Maresa
    Calabro, Luana
    Vardhana, Santosh A.
    Robert, Caroline
    Ibrahim, Ramy
    Anichini, Andrea
    Wolchok, Jedd D.
    Di Giacomo, Anna Maria
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4201 - 4205
  • [27] Neuromuscular blockade management in patients with COVID-19
    Chaves-Cardona, Harold
    Hernandez-Torres, Vivian
    Kiley, Sean
    Renew, Johnathan
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2021, 74 (04) : 285 - 292
  • [28] Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade
    Widman, Adam J.
    Cohen, Bevin
    Park, Vivian
    McClure, Tara
    Wolchok, Jedd
    Kamboj, Mini
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (10): : 1144 - 1144
  • [29] Cerebral hemodynamic alterations in patients with Covid-19
    Sonkaya, Ali Riza
    Ozturk, Bilgin
    Karadas, Omer
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (02) : 435 - 439
  • [30] Choroidal Microvascular Alterations in COVID-19 Patients
    Shrivastav, Ankita
    Zhou, Wenting Sandy
    Ng, Sean
    Ding, Jianbin
    Gilada, Trupti
    Chua, Chun Hau
    Dutt, Shibjash
    Natarajan, Sundaram
    Agrawal, Rupesh
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (06) : 1122 - 1127
12345